> Selling it to anyone who pays the price seems like a bad idea. Which is inevitably what will happen here the next time the company needs to "maximize sharehol

> Selling it to anyone who pays the price seems like a bad idea. Which is inevitably what will happen here the next time the company needs to "maximize shareholder value" [...] 23andMe is still held exclusively by private capital. Nowhere in the reporting does it note GSK negotiated the right to resell 23andMe data. Furthermore, it specifically notes "[if an option is taken to extend the arrangement for a 5th year], GSK will become 23andMe’s exclusive drug target discovery collaborator." Edit: See searine's thread below for a better discussion of why this is critically important to drug development https://news.ycombinator.com/item?id=17611775 https://news.ycombinator.com/item?id=17611775